Review Update on Topical Therapy for Psoriasis

Verallo-Rowell, Vermén M.; Katalbas, Stephanie S.; Evangelista, Mara Therese P.; Dayrit, Johannes F.

doi:10.1007/s13671-018-0209-x

Cited by 5 publications

(4 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitamin D analogues and calcineurin inhibitors modify both the physical and immune barriers of skin. They both enhance differentiation and limit proliferation in keratinocytes [ 193 , 235 ]. Calcineurin inhibitors also supress the proliferation of T cells, whereas vitamin D analogues inhibit the production of cytokines in macrophages and DCs [ 193 , 235 ].…”

Section: Psoriasis Current Treatment and Future Directionsmentioning

confidence: 99%

Skin Barrier Dysregulation in Psoriasis

Andreas

Bereza-Malcolm

Lynch

et al. 2021

IJMS

View full text Add to dashboard Cite

The skin barrier is broadly composed of two elements—a physical barrier mostly localised in the epidermis, and an immune barrier localised in both the dermis and epidermis. These two systems interact cooperatively to maintain skin homeostasis and overall human health. However, if dysregulated, several skin diseases may arise. Psoriasis is one of the most prevalent skin diseases associated with disrupted barrier function. It is characterised by the formation of psoriatic lesions, the aberrant differentiation and proliferation of keratinocytes, and excessive inflammation. In this review, we summarize recent discoveries in disease pathogenesis, including the contribution of keratinocytes, immune cells, genetic and environmental factors, and how they advance current and future treatments.

show abstract

Section: Psoriasis Current Treatment and Future Directionsmentioning

confidence: 99%

Skin Barrier Dysregulation in Psoriasis

Andreas

Bereza-Malcolm

Lynch

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…However its mechanism in psoriasis pathogenesis is still unclear [14,15]. Many reports suggest that Th1 cells may mediate or maintain the disease process [16].…”

Section: Discussionmentioning

confidence: 99%

Assessment of the Level of Interferon-Gamma in the Pathogenesis of Psoriasis

Gharib¹

2019

AII

View full text Add to dashboard Cite

Background: Psoriasis is a chronic autoimmune condition characterized by infiltration of keratinocytes by inflammatory cells that cause scaling on the skin surface. Psoriasis is considered now as T cell-mediated disease. INF-γ is considered a key cytokine in the pathogenesis of psoriasis.Objectives: To evaluate the level of IFN gamma in order to recognize its role in the pathogenesis of psoriasis and its relation to the severity of the disease. Materials and Methods:We investigated the level of serum IFN-γ in 40 patients with psoriasis and in 25 healthy controls by ELISA Kit. We used the PASI score to assess the severity of psoriasis. Results:The serum levels of IFN-γ were elevated in all patients with psoriasis but not in all healthy controls. Also, the serum levels of IFN-γ were correlated with the severity of disease in psoriatic patients. Conclusion:The level of IFN-γ can be used as a useful estimate of the severity of the disease and may be used in daily practice as prognostic follow-up marker.

show abstract

“…Despite its considerable effect on quality of life, psoriasis is underdiagnosed and undertreated. 10 , 11 Based on the extent of involvement and affection on the quality of life, the treatment of psoriasis is individualized with either topical therapy with or without phototherapy for mild‐to‐moderate cases, 12 to systemic treatments involving small molecules or biologics for moderate‐to‐severe cases. 13 Clinical studies of selective biologics that target the immune system have demonstrated that blockade of cytokines such as TNFα, IL‐23 and IL‐17A results in almost complete disease recovery, 13 although extended use can cause serious side effects.…”

Section: Introductionmentioning

confidence: 99%

Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model

Gago-López

Arnal

Pérez

et al. 2021

Experimental Dermatology

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease without cure. Systemic and biological therapies are the most effective treatments for patients with severe psoriasis.However, these drugs can cause serious side effects from extended use. Safe and effective topical drugs are needed to decrease psoriatic plaques and reduce the risk of adverse effects. Amygdalin analogues are stable small molecules that showed benefits in psoriasis xenografts to immune-deficient mice by systemic application. However, whether topical application of these amygdalin analogues could reduce the progression of the psoriatic phenotype in an immune-competent organism is unknown. Here, we analyse the efficiency of topical application of an amygdalin analogue cream on a well-established genetic and immune-competent mouse model of psoriasis. Topical application of an amygdalin analogue cream ameliorates psoriasis-like disease in mice, reduces epidermal hyperplasia and skin inflammation. Amygdalin analogue treatment leads to reduced expression of local pro-inflammatory cytokines, but systemic proinflammatory cytokines that are highly expressed in psoriasis patients such as IL-17A, IL6 or G-CSF are also decreased. Furthermore, expression of important mediators of psoriasis initiation and epidermal hyperplasia, such as TNFa, S100A9 and TSLP, is decreased in lesional epidermis after amygdalin analogue treatment. In conclusion, we show that amygdalin analogue reduces the proliferative capacity of psoriasis-like stimulated keratinocytes and their inflammatory response in vivo and in vitro. These results suggest that topical application of amygdalin analogues may represent a safe and effective treatment for psoriasis.

show abstract

Review Update on Topical Therapy for Psoriasis

Cited by 5 publications

References 77 publications

Skin Barrier Dysregulation in Psoriasis

Skin Barrier Dysregulation in Psoriasis

Assessment of the Level of Interferon-Gamma in the Pathogenesis of Psoriasis

Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model

Contact Info

Product

Resources

About